Senior Director, Clinical Science, Oncology Early Development; Hybrid

Senior Director, Clinical Science, Oncology Early Development (Hybrid)
* This site uses cookies to provide you with an optimal user experience. The cookies include Strictly Necessary and Functional cookies to ensure the site operates as intended (language preference, time zone and workload balance). These cookies are first party cookies, end with the session and are exempted from consent. In addition, this site also uses a Google Analytics Cookie to measure and improve the performance of our site.

All information these cookies collect is aggregated and therefore anonymous. By clicking on the ‘Accept Cookies’ button, you are accepting this Performance cookie.  You may use this site if you click on the ‘Reject Cookies’ button. To revoke your consent of the Performance cookie, clear your cookies within your browser settings.*### Senior Director, Clinical Science, Oncology Early Development (Hybrid)
Apply:
Hybrid:
USA
- New Jersey
- Rahway:
USA
- Massachusetts
- Boston (MA Parcel B Laboratory):
USA
- Pennsylvania
- Upper Gwynedd:
USA
- California
- South San Francisco (Grand Ave):
Full time:
Posted Today:
End Date:
November 5, 2026 (13 days left to apply):
R423797
** Job Description
** The Senior Director, Clinical Science, Oncology Early Development is responsible for providing strategic Clinical Science leadership for novel assets from candidate transition through first-in-human development and clinical clinical proof-of-concept. Reporting to the Executive Director, this role contributes to the early development and scientific platform strategy by applying deep expertise in early-phase oncology, translational medicine, biomarker strategy, and first-in-human (FIH) trail design to shape development plans, strengthen scientific rigor and enable objective, data-driven decision-making across the early oncology portfolio.  

The Senior Director integrates emerging clinical, pharmacokinetic, pharmacodynamic, biomarker, safety, and external scientific evidence to inform indication strategy, dose escalation and optimization, cohort expansion, and proof-of-concept assessments. The role partners closely with Section Heads, Asset Leads, Early Program Development Team Leads, study teams, and cross-functional leaders to guide study design, data interpretation, issue resolution, and program decisions.  This role has a strong strategic orientation and is expected to shape how Clinical Science work is performed across the Oncology Early Development portfolio, including standardization of practices, alignment of scientific approaches, and integration of insights across assets.

The Senior Director may have responsibility for direct management and development of multiple Clinical Scientists and is expected to provide leadership, coaching, and clear direction within a matrix environment.  The role requires close collaboration with Clinical Operations, Regulatory Affairs, Biostatistics and Data Management, Drug Safety and Pharmacovigilance, Translational Medicine, Medical Affairs, and other key partner functions, as well as contribution to governance discussions and senior leadership reviews.

** Key Responsibilities*
* ** Early Development and Clinical Science Strategy*
* * Provide strategic Clinical Science leadership across Oncology Early Development, including multiple studies, programs, and assets.
* Contribute to early clinical development strategy from candidate transition through first-in-human evaluation and clinical proof-of-concept by providing Clinical Science input on development opportunities, scientific considerations, portfolio risks, and implications of emerging internal and external data.
* Partner with Section Heads, Asset Leads, Early Program Development Team Leads, and cross-functional leaders to support alignment of Clinical Science activities with broader program and disease area objectives.
* Integrate disease biology, mechanism of action, translational evidence, competitive landscape, and emerging internal and external data to identify development opportunities, risks, and key decision points.
* Connect insights across studies and assets to inform portfolio decisions and future development.  
** Standardization and Scientific Consistency*
* * Establish and advance consistent Clinical Science standards for early development planning, medical data review, dose-escalation meetings, data interpretation, and key deliverables.
* Promote scientific consistency across studies while preserving flexibility for asset-specific biology, modality, and…